Mulham Ombada, MD
@MOmbada1
Followers
157
Following
839
Media
13
Statuses
163
HPM Fellow @RoswellPark | IM Residency @Upstatenews | Interests: #MedEd #PallOnc #MalignantHem | Aspiring Oncologist | Views my own
Buffalo, NY
Joined July 2023
Glad to share that my article: “Secondary T-cell Lymphoma following CAR-T cell therapy: Incidence and Potential Causes” is published. Grateful for the continuous support from my mentors!. #Teresa Gentile @ElizabethPrsic @realbowtiedoc #Julian Sprague @ASH @hemeoncfellow
3
2
24
RT @drjgauthier: In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet https://t.co….
thelancet.com
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex...
0
8
0
RT @FawziAbuRous: August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung canc….
0
12
0
RT @DrYukselUrun: Breast cancer care must not depend on geography or GDP. A blueprint for equity, not just efficiency. #CancerCare #GlobalO….
0
13
0
RT @RahulBanerjeeMD: Excellent @JCO_ASCO editorial by @SagarLonialMD @myelomaMD about CARTITUDE-1, with 5-yr PFS of 33% off all treatment i….
0
5
0
RT @realbowtiedoc: Maintaining our short #video summaries of the #Top10Tips paper for #hpm on #survonc published in.@PalliativeMed_j. Pres….
0
7
0
RT @realbowtiedoc: Nothing gives me a boost like meeting with my @PallOncCoP family. Combine that with my love of #nerdy 🤓 and this is goin….
0
7
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory myeloma ac….
0
12
0
RT @oncodaily: My first E-Poster presentation at LLM Congress 2024 - @MOmbada1 .@llmcongress . #LLMCongress2024 #H….
0
1
0
My first E-Poster presentation ✅ .Attended amazing learning sessions ✅ . Grateful for the collaboration opportunity with my respectful mentors & colleagues 🙏 . Thank you @llmcongress for this great meeting experience✌️ . #MedTwitter #LLMCongress2024
2
0
6
RT @oncodaily: Difficult Case of a Severe Refractory ITP - @MOmbada1 .@BloodJournal . #BloodJournal #Cancer #OncoD….
oncodaily.com
Mulham Ombada: Difficult Case of a Severe Refractory ITP / Blood Journal, cancer, James B. Bussel, Ming Hou, Mulham Ombada, OncoDaily, Oncology, Oriana
0
1
0
RT @PallOncCoP: Grateful to everyone who works in the palliative care space- ensuring patients receive holistic and goal concordant care at….
0
8
0
Excited to share that our new abstract “Struck by Tsunami: Difficult Case of a Severe Refractory ITP” got approved for publication at @BloodJournal. Grateful for the tremendous support by my mentor Dr. Teresa Gentile and all collaborators. #MedTwitter #ITP #SuppOnc
1
0
19
RT @realbowtiedoc: The #pallonc study that rocked #ESMO24 in @NEJM . Ph 2 trial of ponsegromab antiGDF-15 in 185 pts: .⬆️weight gain ⚖️.⬆️a….
0
15
0
RT @NazliDizman: 🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedic….
0
90
0
RT @virenkaul: Visual on why 14G = large bore . Not 16G, not 18G . Ask your team deliberately: “What size IV access do we have?” As opposed….
0
34
0
RT @realbowtiedoc: @CvonGunten is a true #pallonc legend and foundational for #hpm #hapc training. Grateful to have caught him at #hapc23….
0
8
0
Thank you Karyopharm Therapeutics for the invite! . Looking forward attending Dr. Niesvizky @RubenNiesvizky presentation on Friday, October 18th! . #MedTwitter #LLM #Myeloma
0
0
6
RT @VivekSubbiah: ⭐️Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers @AACR @CD_AACR @ElizSMcKenna….
0
7
0